Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia.

Yamamoto R, Yokoyama A, Yoneda M, Ohashi K, Hosoda T, Kagoo T, Boku S, Ueno H, Yano T.

Ann Hematol. 2014 Dec;93(12):2081-2. doi: 10.1007/s00277-014-2119-8. Epub 2014 May 27. No abstract available.

PMID:
24863693
2.

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.

Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P; European ALMA Investigators.

Leuk Res. 2015 Mar;39(3):296-306. doi: 10.1016/j.leukres.2014.12.013. Epub 2014 Dec 31.

PMID:
25601157
3.

Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report.

Todaro J, Bollmann PW, Rother ET, del Giglio A.

Sao Paulo Med J. 2015 May-Jun;133(3):271-4. doi: 10.1590/1516-3180.2012.6790006. Epub 2014 Sep 19.

4.

Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.

Ritchie EK, Feldman EJ, Christos PJ, Rohan SD, Lagassa CB, Ippoliti C, Scandura JM, Carlson K, Roboz GJ.

Leuk Lymphoma. 2013 Sep;54(9):2003-7. doi: 10.3109/10428194.2012.762093. Epub 2013 Feb 7.

5.

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.

Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U; Study Alliance Leukemia Group.

Leukemia. 2016 Mar;30(3):555-61. doi: 10.1038/leu.2015.306. Epub 2015 Nov 2.

PMID:
26522083
6.

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.

Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F.

Leukemia. 2012 Nov;26(11):2428-31. doi: 10.1038/leu.2012.153. Epub 2012 Jun 5. No abstract available.

7.

5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.

Ivanoff S, Gruson B, Chantepie SP, Lemasle E, Merlusca L, Harrivel V, Charbonnier A, Votte P, Royer B, Marolleau JP.

Am J Hematol. 2013 Jul;88(7):601-5. doi: 10.1002/ajh.23464. Epub 2013 May 30.

8.

Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia.

Bayraktar UD, Domingo GC, Schmit J, Pereira D.

Leuk Lymphoma. 2011 May;52(5):913-5. doi: 10.3109/10428194.2010.551570. Epub 2011 Mar 21. No abstract available.

PMID:
21417821
9.

Salvage induction chemotherapy after azacitdine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation.

Yee KW, Brandwein J, Schimmer AD, Gupta V, Del Bel R, Xu W, Minden MD, Schuh AC.

Br J Haematol. 2014 Jul;166(2):303-6. doi: 10.1111/bjh.12844. Epub 2014 Mar 21. No abstract available.

PMID:
24650042
10.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR.

J Clin Oncol. 2010 Feb 1;28(4):562-9. doi: 10.1200/JCO.2009.23.8329. Epub 2009 Dec 21.

11.

Azacitidine in AML: a treatment option?

Huls G.

Blood. 2015 Jul 16;126(3):283-4. doi: 10.1182/blood-2015-06-648071.

12.

Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.

Niscola P, Tendas A, Cupelli L, Giovannini M, Piccioni D, Scaramucci L, Dentamaro T, Del Poeta G, de Fabritiis P.

Acta Haematol. 2015;133(1):64-6. doi: 10.1159/000363643. Epub 2014 Aug 14. No abstract available.

PMID:
25139255
13.

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.

Thépot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing Koka A, Stamatoullas A, Chaury MP, Dartigeas C, Cheze S, Banos A, Morel P, Plantier I, Taksin AL, Marolleau JP, Pautas C, Thomas X, Isnard F, Beve B, Chait Y, Guerci A, Vey N, Dreyfus F, Ades L, Ifrah N, Dombret H, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA); Groupe Ouest-Est des Leucémies Aiguës; Maladies du Sang (GOELAMS).

Am J Hematol. 2014 Apr;89(4):410-6. doi: 10.1002/ajh.23654. Epub 2014 Feb 6.

14.

Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.

Bhatnagar B, Duong VH, Gourdin TS, Tidwell ML, Chen C, Ning Y, Emadi A, Sausville EA, Baer MR.

Leuk Lymphoma. 2014 Jul;55(7):1533-7. doi: 10.3109/10428194.2013.856425. Epub 2014 Feb 4.

PMID:
24144313
15.

Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.

Falantes JF, Calderón C, Márquez-Malaver FJ, Aguilar-Guisado M, Martín-Peña A, Martino ML, Montero I, González J, Parody R, Pérez-Simón JA, Espigado I.

Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):80-6. doi: 10.1016/j.clml.2013.09.014. Epub 2013 Oct 1.

PMID:
24220615
16.

Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia.

Thomas S, Schelker R, Klobuch S, Zaiss S, Troppmann M, Rehli M, Haferlach T, Herr W, Reichle A.

Haematologica. 2015 Jan;100(1):e4-6. doi: 10.3324/haematol.2014.115055. Epub 2014 Sep 26. No abstract available.

17.

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.

Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Borthakur G, Verstovsek S, Faderl S, Cortes J, Kantarjian H.

Cancer. 2009 Dec 15;115(24):5746-51. doi: 10.1002/cncr.24661.

18.

A 5-day outpatient regimen of azacitidine is effective and well tolerated in patients with acute myeloid leukemia unsuitable for intensive chemotherapy.

O'Reilly MA, McHale C, Almazmi A, Hameed A, Benjamin D, O'Connell N, Murphy P, Quinn J, Thornton P, O'Gorman P, Frankova H, Sargent J, Verburgh E, McHugh J, Evans P, Enright H.

Leuk Lymphoma. 2014 Dec;55(12):2950-1. doi: 10.3109/10428194.2014.904512. Epub 2014 Apr 22. No abstract available.

PMID:
24628297
19.

Outcome of therapy-related myeloid neoplasms treated with azacitidine.

Fianchi L, Criscuolo M, Lunghi M, Gaidano G, Breccia M, Levis A, Finelli C, Santini V, Musto P, Oliva EN, Leoni P, Aloe Spiriti A, D'Alò F, Hohaus S, Pagano L, Leone G, Voso MT.

J Hematol Oncol. 2012 Aug 1;5:44. doi: 10.1186/1756-8722-5-44.

20.

First Steps Towards Successful Post-Transplantation Therapy for Myeloid Malignancies after Allogeneic Blood Stem Cell Transplantation.

Schroeder T, Kobbe G.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1703-4. doi: 10.1016/j.bbmt.2015.08.012. Epub 2015 Aug 12. No abstract available.

PMID:
26277403
Items per page

Supplemental Content

Write to the Help Desk